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Background: Childhood asthma is a common condition. Currently there is no validated objective test which can be
used to guide asthma treatment in children. This study tests the hypothesis that the addition of fractional exhaled
nitric oxide (FENO) monitoring in addition to standard care reduces the number of exacerbations (or attacks) in
children with asthma.
Methods: This is a multi-centre, randomised controlled study. Children will be included of age 6–16 years who have a
diagnosis of asthma, currently use inhaled corticosteroids (ICSs) and have had an exacerbation in the previous 12months.
Exclusion criteria include being unable to provide FENO measurement at baseline assessment, having another chronic
respiratory condition and being currently treated with maintenance oral steroids. Participants will be recruited in both
primary and secondary care settings and will be randomised to either receive asthma treatment guided by FENO plus
symptoms (FENO group) or asthma treatment guided by symptoms only (standard care group). Within the FENO group,
different treatment decisions will be made dependent on changes in FENO. Participants will attend assessments 3, 6, 9
and 12months post randomisation. The primary outcome is asthma exacerbation requiring prescription and/or
use of an oral corticosteroid over 12months as recorded by the participant/parent or in general practitioner records.
Secondary outcomes include time to first attack, number of attacks, asthma control score and quality of life.
Adherence to ICS treatment is objectively measured by an electronic logging device. Participants are invited
to participate in a “phenotyping” assessment where skin prick reactivity and bronchodilator response are
determined and a saliva sample is collected for DNA extraction. Qualitative interviews will be held with participants
and research nurses. A health economic evaluation will take place.
Discussion: This study will evaluate whether FENO can provide an objective index to guide and stratify asthma
treatment in children.
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the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
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Background and rationale {6a}
There are one million children in the UK with asthma [1].
Although asthma cannot be cured, there is effective
treatment to control symptoms and reduce the risk of
asthma attacks. There is an urgent need to identify and
validate a biomarker to guide asthma treatment and provide
objective measurements to support clinical decision-making,
e.g. when to use which treatment and when to step down
treatment. Fractional exhaled nitric oxide (FENO) is a
surrogate marker for eosinophilic airway inflammation [2–5]
and, since eosinophils are seen in the airways of people with
asthma [6], it was assumed that FENO measurements
could be used to improve asthma control.
The evidence from clinical trials, however, is that the
addition of FENO monitoring to usual care does not
improve asthma control [7, 8]. Sputum eosinophilia is
known to be a temporary phenomenon in children [9], and
this temporality at least partly explains the poor correlation
between FENO and current and future asthma control [10–
13] and also the failure of FENO-guided treatment to
improve symptomatic asthma control [14]. In contrast,
changes in FENO concentrations are more clearly observed
in the context of asthma attacks (sometimes just called
attacks). For example, FENO rises before an attack [15] and
falls afterwards [16]. The relationship between FENO and
attack is replicated by the correlation between airway
eosinophilia and asthma attack; asthma treatment guided by
airway eosinophilia reduces asthma attacks in adults [17] and
children [18] (the latter with borderline significance in a
small study). Of note, asthma control was not improved in
the intervention arm compared to the standard treatment
arm in these studies [17, 18]. Eosinophilic inflammation is
suppressed by treatment with inhaled corticosteroids (ICS),
and FENO increases after unsuccessful reduction [19] or
cessation [20] of ICS. Together these observations show how
airway eosinophilia is an index of attack risk (but not of poor
symptomatic asthma control) which can be suppressed with
ICS and which is correlated with FENO.
Until recently, the application of FENO into clinical
practice has been uncertain, as the answer to the
question “What is a significant change in FENO?” was
unknown. Previous trials adopted FENO cut-offs based
on comparisons between children with and without
asthma or simply empirical values, e.g. 20, 30, 40 parts
per billion (ppb). Our recent work has demonstrated
that FENO values may rise and fall, independently of
asthma, by up to 50% over 2- and 4-month intervals
[12]. Based on these observations, we will, for the first
time in a clinical trial, use percentage change in FENO
to interpret repeated FENO measurements.
We will deliver a rigorous and adequately powered trial to
confirm whether FENO-guided algorithm-based asthma
treatment prevents asthma attacks. This trial is timely given
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tute for Health and Care Excellence (NICE) [21] which
stated that “FENO measurement is recommended as an
option to support asthma management…in people who
are symptomatic despite using inhaled corticosteroids”
and also stated that “The Committee … accepted there
is a need for more evidence on which protocols offer
the safest and most optimal asthma management when
used in UK clinical practice”. This trial will evaluate the
clinical efficacy of our algorithm-guided intervention on
asthma attacks while describing the relationship be-
tween FENO, asthma control and attacks. Our hypoth-
esis is that the proportion of children with ≥ 1 asthma
attack over 12 months will be reduced when asthma
treatment guided by FENO plus symptoms is compared
to treatment guided only by symptoms.
Aim and objectives {7}
The aim of the study is to compare treatment guided by
FENO and symptoms against treatment guided by symptoms
alone (standard care), in children with asthma who are at
risk of an asthma attack, in terms of the presence of any
asthma attacks over 12months requiring prescription and/or
use of an oral corticosteroid (OCS).
The objectives are:
 To recruit 502 eligible children
 For recruited children to complete an assessment
including spirometry, Asthma Control Test (ACT)
or the Childhood Asthma Control Test (CACT) and
FENO at baseline
 To randomise children to intervention (treatment
guided by FENO and symptoms) or standard care
(treatment guided by symptoms alone)
 To monitor adherence to inhaled corticosteroid
treatment with an electronic logging device
 To repeat FENO and ACT/CACT at 3, 6, 9 and 12
months and change asthma treatment according to
the trial protocol
 On an optional basis, to collect saliva for DNA
isolation to allow genetic analysis in a separate study
 On an optional basis, for children (approximately
200) to have skin prick reactivity and bronchodilator
response determined for a mechanistic study
 To undertake a qualitative process evaluation of
approximately 20 children and approximately 15
members of trial staff representing a number of roles
across different sites, to explore experiences and
acceptability of the intervention
 To undertake an economic evaluation to assess the
healthcare costs (e.g. asthma-related hospital admissions
and visits to/from relevant health professionals,
asthma medications) and other related costs (e.g.
parents’ time off work) and quality of life effects(quality-adjusted life years [QALYs]) of the interven-
tion compared to routine care
 To compare the primary and secondary outcomes
between treatment arms.
Trial design {8}
This is a multi-centred randomised trial comparing the
efficacy of asthma treatment guided by symptoms and
FENO with asthma treatment guided by symptoms alone
for risk of asthma attack.
The research design also includes an evaluation of
healthcare costs (including primary and secondary care
contacts and asthma treatment). The qualitative process
evaluation using established research techniques will
explore experiences and determine the acceptability of
the intervention by interviewing 20 children in the
intervention arm and 15 research nurses until
saturation of themes is achieved
Methods: participants, interventions and outcomes
Study setting {9}
We are recruiting children in secondary care sites
across the UK and in primary care centres in the East
of England.
Eligibility criteria {10}
The inclusion criteria are:
1. Asthma diagnosed or confirmed by consultant
paediatrician or respiratory/asthma specialist nurse
(or Read code for asthma if recruited in primary care)
2. Patient aged 6 years or older and has not reached
the date of 16th birthday (children < 6 years find it
difficult to provide FENO measurements [22])
3. Currently prescribed ICSs in a device that can be
fitted with a Smartinhaler (electronic logging device):
the maximum dose for children aged < 12 is 1000 μg
budesonide equivalent (BUD) per day; the maximum
dose for children aged ≥ 12 is 2000 μg BUD per day.
4. Parent/patient-reported asthma attack treated with
at least one course of OCS in the 12 months prior
to recruitment.
The exclusion criteria are:
1. Unable to provide FENO measurement at baseline
assessment
2. Other chronic respiratory conditions which also
manifest attacks
3. Current treatment with maintenance oral steroids.
Who will take informed consent? {26a}
Consent is taken by researchers trained in Good Clinical
Practice (GCP) and with experience in working with
Table 1 Treatment steps for the experimental intervention. More details in relation to the treatment steps are provided in Appendix
1 of the supplement; a detailed decision tree is given in Appendix 2 of the supplement
Step Algorithm 1 (FENO high) Algorithm 2 (FENO not high)
1 Short-acting beta-agonist (SABA) as required only SABA as required only
2 Budesonide (or beclomethasone) 200 μg daily plus SABA Budesonide (or beclomethasone 200 μg twice daily plus SABA
3 Budesonide (or beclomethasone) 400 μg OR fluticasone 200 μg daily
plus SABA
Budesonide (or beclomethasone) 400 μg OR fluticasone 200 μg daily
plus SABA
4 Budesonide (or beclomethasone) 800 μg OR fluticasone 500 μg daily
plus SABA
Add long-acting beta-agonist (LABA)
5 Only for≥ 12-year-olds: Budesonide (or beclomethasone 1600 μg daily
or fluticasone 1000 μg daily plus SABA. Go to step 6 for < 12-year-olds
Add leukotriene receptor antagonist
6 Add LABA in fixed dose combination Budesonide 800 μg or fluticasone 500 μg daily in fixed dose
combination
7 Add leukotriene receptor antagonist Only for≥ 12-year-olds. Budesonide (or beclomethasone 1600 μg daily
or fluticasone 1000 μg daily plus SABA. Go to step 8 for < 12-year-olds
8 Refer for specialist assessment Refer for specialist assessment
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qualitative interviews is taken from qualitative researchers
with GCP training. Written consent is obtained from
parent(s)/carer(s) and (where appropriate) from the
participant. If the child does not provide written consent,
he/she will be asked to give verbal assent.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Consent includes the option to give permission to
collect saliva for DNA extraction and for linkage of data
to other data sources.
Interventions
Explanation for the choice of comparators {6b}
The comparator is FENO. Justification for this is given in
the “Background and rationale” section.Table 2 Treatment steps for the control intervention. More details in
detailed decision tree is shown in Appendix 2
Treatment step Daily ICS dose μg
budesonide or
equivalent
Delivery device used prio
1 0 No ICS
2 200 Very low dose ICS
3 400 Low dose ICS
4 400 ICS + long-acting beta-ag
(LABA) combination inha
5 400 Add on leukotriene rece
antagonist (LTRA)‡
6 800 High dose ICS
7
For 12–16 year olds
(go to step 8 for children < 12)
1600 High dose ICS
8Intervention description {11a}
In the intervention arm, asthma treatment is guided by
FENO and symptoms. Table 1 describes the treatment
steps. The experimental intervention and subsequent
adjustment of treatment steps are applied at recruitment
and at each of the follow-up visits (3, 6, 9 and 12months).
In the standard care arm, asthma treatment is guided by
symptoms alone; adjustment of treatment steps are applied
at recruitment and at each of the follow-up visits (3, 6, 9
and 12months). Table 2 describes the treatment steps,
which are in accordance with national guidelines [23].
Algorithm
Web-based software is used to apply a decision tree
algorithm which is described in the supplement. At each
assessment (baseline and 3, 6, 9 and 12months) the
researcher enters the participant FENO, CACT or ACTrelation to the treatment steps are provided in Appendix 1; a
r to enrolment used after enrolment
Short-acting beta-agonist (SABA) as required only
Budesonide (or equivalent) 100 μg twice daily plus SABA
Budesonide (or equivalent) 200 μg twice daily plus SABA
onist
ler
Budesonide (or equivalent) 200 μg twice daily plus SABA and
LABA (dose depending on ICS molecule used)
ptor Budesonide (or equivalent) 200 μg twice daily plus SABA, LABA
and LTRA
Budesonide (or equivalent) 400 μg twice daily plus SABA, LABA
(dose depending on ICS molecule used) and LTRA
Budesonide (or equivalent) 800 μg twice daily plus SABA, LABA
and LTRA
Refer for specialist opinion
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months assessments, information on adherence to inhaled
corticosteroid medication is also entered into the
software. The algorithm within the web-based software
considers the participant’s age, current medication,
asthma control, adherence (at the 3, 6, 9 and 12months
assessments) and (in the FENO-guided arm) FENO before
recommending what treatment should be taken. Within
the FENO-guided arm, there are two “ladders” of escalat-
ing and reducing treatment steps, and the change in FENO
determines which ladder is applied. For example, if the
participant has poor asthma control and high FENO then
their ICS treatment is increased, whereas if their FENO
has not risen then they start long-acting beta-agonist
(LABA) treatment. Based on our earlier work [12], a
change of > 50% is defined as a significant change. The al-
gorithm includes a number of “safety netting” instructions
which allow only one treatment step up in the context of
(1) elevated FENO and controlled symptoms, (2) elevated
FENO, uncontrolled symptoms and poor adherence and
(3) persistently low FENO and uncontrolled symptoms. In
both arms, the algorithm allows for a single step up in
treatment when the participant has poorly controlled
symptoms but has poor adherence, and also recommends
“refer specialist opinion” (i.e. the researcher should ask an
asthma specialist to review the participant) if the highest level
of treatment is reached but control remains poor or one of
the “safety netting” instances occurs. At their discretion, local
clinical teams may choose not to apply the algorithm recom-
mendations and to make their own clinical recommendation
on treatment, and if they do this, the reason is recorded.
Table 3 summarises the information captured at each
assessment. At each visit, the following is assessed:Table 3 Timing of outcomes to be assessed
Time
Basel
FENO ✓
Smartinhaler® data
Respiratory case report form (current medication, recent asthma
history and attacks, inhaler technique, etc.)
✓
Asthma Control Test ✓
Paediatric Asthma Quality of Life Questionnaire ✓
Spirometry (FEV1) and height ✓
Weight ✓
Asthma attacks ✓
Asthma-related healthcare and other related resource use ✓
Mechanistic studies
Bronchodilator response (optional) ✓
Skin prick testing (optional) At an
Saliva for DNA extraction (optional) At an Asthma symptoms are measured using the ACT
(or CACT [24]), and a score of < 20 is defined as
poor control.
 FENO, using the standard methodology. Although
FENO is measured in children in the standard care
arm at recruitment (and at each of the follow-up
visits), the results of the FENO will not be used in
treatment decisions for this arm of the trial. FENO
results are recorded once the child has left the room.
 Forced expiratory volume in one second (FEV1),
using the standard methodology.
 Inhaler technique.
At the baseline and 12 months assessments, the
following are ascertained:
 Weight
 Quality of life using the Paediatric Asthma Quality
of Life Questionnaire (PAQLQ) [25].
At the 3, 6, 9 and 12months assessments, the
following are assessed:
 Adherence to treatment
 Asthma exacerbation since the last study visit
 Healthcare resource use since the last study visit.
Additionally, participants have the option of
providing a saliva sample for DNA extraction and
analysis, having skin prick reactivity to egg, cat
dander, grass and house dust mite and bronchodilator
responsiveness assessed. Methodologies are described
in the supplement.point
ine 3 months 6 months 9 months 12 months
✓ ✓ ✓ ✓
✓ ✓ ✓ ✓
✓ ✓ ✓ ✓
✓
✓ ✓ ✓ ✓
✓
✓ ✓ ✓ ✓
✓ ✓ ✓ ✓
y assessment
y assessment
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Adherence is determined by the researcher at all
visits. The definition of adequate adherence is either
> 70% adherence as measured by the Smartinhaler®
electronic logging device or by participant/parent
report of being adherent most or all of the time. This
definition allows for missing Smartinhaler® data, e.g.
at baseline assessment, failure of the device or non-
availability of the device, and also the real-world sce-
nario where there is a discrepancy between the Smar-
tinhaler® data and participant/parent report.Qualitative interviews
In a qualitative process evaluation to explore experiences
and ascertain acceptability of the intervention, and to solicit
in-depth feedback on the process of taking part in this trial,
children in the intervention arm (n= 20) will be invited to
give a qualitative interview with an experienced qualitative
researcher. A range of trial staff representing a number of
roles and across different sites (n= 15) will also be inter-
viewed to understand the feasibility of intervention delivery
from provider perspectives and to access any additional ob-
servations made around acceptability/process. We will inter-
view staff in Aberdeen initially and then researchers in
Scotland (due to proximity to the trial office, where the
qualitative researcher will be based) and English centres se-
lected for success in participant recruitment and retention in
the trial. Interviews may be carried out over the telephone.
Research nurses will be invited for interview who do and
who do not have previous expertise in paediatric respiratory
medicine, and also research nurses who have more than ap-
proximately 10 years’ experience and approximately less than
five years’ experience to gain insight into whether respiratory
and/or research experience affect perspectives. Our inter-
views will explore with healthcare staff decision-making
around not applying the algorithm: for example, does confi-
dence in the algorithm grow over time? Is there “intelligent
non-concordance”, e.g. reluctance to increase (or step up)
treatment if the participant is already on high level treatment
or also reluctance to not step down if on low treatment (es-
pecially if stopping)? Interviews will continue until saturation
of emerging themes. Further details are in the supplement.Criteria for discontinuing or modifying allocated
interventions {11b}
Adherence to intervention is facilitated by the web-
based design of the treatment algorithm.Strategies to improve adherence to intervention {11c}
Adherence to the intervention is facilitated by the web-
based software which presents the researcher clear instruc-
tions as to what change in treatment (if any) is required.Relevant concomitant care permitted or prohibited
during the trial {11d}
Usual care for participants continues throughout the
trial. There is nothing prohibited.
Provisions for post-trial care {30}
Standard care is provided within the UK National
Health Service (NHS).
Outcomes {12}
Primary outcome
The primary outcome is prescription for (and/or use of) ≥
1 course of OCS for asthma attacks in the 12months after
randomisation (yes/no). The decision to prescribe OCS is
made by clinicians independent of the research team and
working in accordance with the national guidelines [23].
The primary outcome is captured from parental report at
the 3, 6, 9 and 12month assessments. Where data are not
available at 12months, the general practice (GP) at which
the participant is registered is contacted to capture
primary outcome data.
Secondary outcomes
 Time to first attack
 Number of attacks during follow-up
 Need for unscheduled healthcare assessment during
follow-up (yes/no)
 Number of unscheduled health assessments
 Asthma control during follow-up (i.e. age
-appropriate ACT score ≥ 20 [24])
 Spirometry during the 12months follow-up (i.e. %FEV1,
standardised to Global Lung Function Initiative [26])
 FENO during the 12 months follow-up
 Dose of ICS during the 12 months follow-up
(i.e. daily dose of budesonide equivalent averaged
over 3 months)
 Paediatric Asthma Quality of Life Questionnaire
(PAQLQ) [25] score at 12 months
 Qualitative outcomes from interviews
 Health economic evaluation (derived from GP
records and participant reported data).
Participant time line {13}
See Fig. 1 for the participant’s time line through the trial.
Sample size {14}
Our meta-analysis finds a relative 33% reduction in the
proportion with ≥ 1 attack receiving FENO-guided treat-
ment [27]. Assuming an attack proportion of 44% for
the symptom-guided treatment group and 29.5% for the
intervention group, we have 90% power with 5% signifi-
cance (two-sided) if we recruit 238 children per group.
Fig. 1 Flow diagram illustrating the participant’s journey through the RAACENO trial
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502 children (i.e. 251 per group).
Recruitment {15}
Eligible individuals are identified by their usual
clinical team and are sent a letter of invitation which
is accompanied by a short participant and parentinformation sheet. Parent information sheet and the
age-appropriate children’s information sheet. A
follow-up telephone call is arranged to establish
whether an appointment should be made for a face-
to-face meeting where eligibility is confirmed, consent
taken, baseline details collected and randomisation
performed.
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Sequence generation {16a}
After consent is given, participants are randomly allocated
to either the intervention or standard care group using a
minimisation algorithm, with stratification by recruiting
centre, age (< 11 or ≥ 11 years) and asthma severity (British
Thoracic Society/ Scottish Intercollegiate Guidelines
Network [BTS/SIGN] treatment step 2, 3 or 4),
including a random element (20%). The primary care
centres are collectively considered as one recruiting
centre for randomisation.
Concealment mechanism {16b}
The web-based randomisation system ensures allocation
concealment.
Implementation {16c}
The allocation sequence generation is embedded in the
trial web site. Research nurses based at sites enroll
participants and randomise them using the web-based
randomisation system.
Assignment of interventions: blinding
Who will be blinded {17a}
There can be no blinding of participants, parents, clinical
staff or the central trial team to the allocated trial arm.
Participants in the standard care arm are blinded to their
FENo results until they have completed the 12months
follow-up.
Procedure for unblinding if needed {17b}
There is no requirement for emergency unblinding
procedures.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Data are collected at baseline and at 3, 6, 9 and 12months.
Plans to promote participant retention and complete
follow-up {18b}
There is a 6-week visit window around each of the
follow-up appointments. Where possible, study follow-
up visits are timed to coincide with routine clinic ap-
pointments. There are no additional plans to enhance
retention to RAACENO.
Data management {19}
All data are entered by site staff onto a web-based case
report form. Data are held on a secure server at the
University of Aberdeen. The central trials team monitor
data entry and ensure that missing data are addressed as
soon as possible after detection.Confidentiality {27}
Data are stored in accordance with GCP and with the
UK Data Protection Acts 1998 and 2018.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis {33}
Saliva samples are collected in Oragene collection kits
(DNA Genotek, Ottawa, ON, Canada) for later DNA
extraction and analysis. A candidate gene is rs1042713.
Analysis
Statistical methods for primary and secondary outcomes {20a}
Analysis will be by intention-to-treat. To determine
whether the intervention leads to reduction in the pri-
mary outcome, logistic regression will be used to com-
pare the primary outcome (yes/no) between treatment
groups adjusting for relevant baseline factors known to
be strongly related to attack at 12 months (age, gender,
the age mother left full-time education, asthma severity
and centre). Number of attacks will be analysed using
Poisson regression adjusting for the same baseline fac-
tors. Time to first attack will be compared between
groups using Cox regression. Secondary outcomes in-
cluding ACT, FENO, FEV1 and dose of ICS will be com-
pared between treatment groups using linear mixed
effects models to account for the correlation between re-
peated measures. The benefit of this approach is inclu-
sion of all individuals where there is ≥ 1 clinical
assessment. Unscheduled healthcare attendance (yes or
no) will be compared between treatment groups using
generalised estimating equations and, if deemed appro-
priate, the number of unscheduled healthcare atten-
dances will be compared using Poisson regression. Full
details will be described in the statistical analysis plan
for the study. Comparison of quality of life (using the
PAQLQ) at the final assessment (12 months) between
treatment groups will be assessed using analysis of co-
variance, adjusting for minimisation variables, baseline
values and other appropriate baseline predictors. The in-
fluence of any missing data on the robustness of the
findings will be examined using sensitivity analyses in-
corporating multiple imputation or other relevant strat-
egies under alternative assumptions.
Interim analyses {21b}
There will be no interim analyses.
Methods for additional analyses (e.g. subgroup analyses) {20b}
We will explore whether outcomes are different between
groups for the stratification variables (gender, age group,
asthma severity). Additionally we will explore whether
an attack was precipitated by an upper respiratory tract
infection, whether the participant was treated with a
leukotriene receptor antagonist or whether the
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framework for the health economic evaluation will adopt
both a cost-effectiveness approach, assessing health gains
in terms of asthma exacerbations prevented, and a cost-
utility approach, assessing gains in QALYs. A thematic
approach will be used to analyse qualitative data.
Methods in analysis to handle protocol non-adherence and
any statistical methods to handle missing data {20c}
Analysis will be by intention-to-treat. We do not plan to
impute missing values, but may consider use of multiple
imputation or other strategies within the sensitivity ana-
lysis (see the section “Statistical methods for primary
and secondary outcomes”).
Plans to give access to the full protocol, participant-level
data and statistical code {31c}
The full protocol is available as a supplement. Non-
identifiable participant-level data may be available on
request to the Chief Investigator (CI), Professor Turner
(s.w.turner@abdn.ac.uk).
Oversight and monitoring
Composition of the coordinating centre and Trial Steering
Committee {5d}
The immediate trial team based in the coordinating centre
(CI, trial manager, data coordinator) meets weekly. On a
monthly basis, the immediate team is joined by the wider
team based in the coordinating centre (statistician, health
economist, qualitative researcher). A Project Management
Group (PMG) and Trial Steering Committee (TSC) oversee
the project. The PMG meets every 3 months and
comprises the CI, grant holders (including clinical,
methodological, statistical, health economic and qualitative
expertise) and the trial office staff. The TSC meets every 6
months and includes an independent chair, clinical and
methodological expertise and lay representative.
Composition of the Data Monitoring Committee, its role
and reporting structure {21a}
The Data Monitoring Committee meets every 6 months.
It includes an independent chair and independent
members with clinical and methodological expertise, and
it reports to the chair of the TSC.
Adverse event reporting and harms {22}
Within RAACENO, we only record any adverse events
(AEs) and serious adverse events (SAEs) relating to use of
the NIOX VERO device or other study assessments. All AEs
(including SAEs) meeting the criteria for recording within
RAACENO are recorded from the time a participant
consents to join the trial until the last trial visit. The
Investigator asks about the occurrence of AEs at every visit.
Open-ended and non-leading verbal questioning of theparticipant is used to enquire about AE occurrence. The In-
vestigator (or delegate) reviews appropriate documentation
(e.g. hospital notes, laboratory and diagnostic reports) related
to the event. The Investigator (or delegate) records all rele-
vant information on the AE form. Site staff are responsible
for notifying the trial office of any AEs. The CI or delegate
will report any related and unexpected serious AEs to the
Research Ethics Committee (REC) within 15 days of the CI
becoming aware of it. All related serious AEs are sum-
marised and reported to the REC, the funder and the TSC in
their regular progress reports. An asthma attack (defined as
an increase in asthma symptoms requiring treatment with
oral corticosteroids) is the primary outcome and is not an
AE.
Frequency and plans for auditing trial conduct {23}
The trial office monitors aspects of the study on an
ongoing basis as described in the study monitoring plan.
The trial is monitored and audited by the sponsor.
Individual sites may be monitored by their local
Research and Development (R&D) departments.
Plans for communicating important protocol amendments
to relevant parties (e.g. trial participants, ethical
committees) {25}
Changes to the protocol require the trial office to seek
permission from the funder, sponsor, REC and NHS
R&D offices.
Dissemination plans {31a}
We will develop a publication and dissemination plan
to include conference presentation(s) and journal
publication(s). We plan to write to all participants
and their families to inform them of the trial results.
We will also plan dissemination to relevant patient
and clinical interest groups.
Discussion
Childhood asthma is a common condition, and there
is a need for an objective test to help guide asthma
management [28]. Additionally there is a desire to
recognise the heterogeneity of asthma by moving
away from a “one size fits all” management strategy,
and instead stratify treatment to the individual [29].
The RAACENO study will rigorously evaluate
whether treatment guided by symptoms plus FENO
reduces asthma attacks compared to symptom-only
treatment.
There have been eight previous randomised
controlled trials (RCTs) which have used FENO to
guide asthma treatment. In only one of these was
there an improvement in asthma control, and in four
there were reduced asthma attacks. This present
study differs from previous trials in (1) being powered
Turner et al. Trials          (2019) 20:573 Page 10 of 11on asthma attacks and not asthma control, (2)
individualising change in FENO by using percentage
change and therefore not using the same cut-off
values for the whole population and (3) having differ-
ent treatment pathways within the FENO-guided
treatment arm depending on FENO values.
A recent study where data from seven of the
previous RCTs were pooled has found that a
relatively large change in FENO occurred before
asthma status changed [30]. This result is consistent
with that of a previous study [12], and together these
data support the relatively large change in FENO used
to trigger change in treatment in the RAACENO
study. This recent work also supports the RAACENO
methodology by finding that percent change in FENO,
and not absolute change in FENO, preceded a change
in asthma status [30]. However, the paper by Fielding
et al. [30] observed that changes in percentage of
FENO preceded loss of asthma control but not of
asthma attack, but in contrast RAACENO is powered
on attacks and not control. The methodology used in
RAACENO is substantially different from those of the
previous RCTs. The RAACENO trial will report on
its findings in early 2021.Trial status
Recruitment was completed on 8th August 2019. The
current protocol is version 5 (dated 08/03/2019).Abbreviations
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